SOX10 Regulates Melanoma Metastasis Through the IRF1 ‐ ITGA3 / EphA2 ‐ FAK Pathway
Cancer Science · 2025-11 · 116 (11) · 3052-3065
DOI: 10.1111/cas.70173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 13.08.2025. Verfasst von Ryuya Kaminaka und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan. Hauptthemen laut MEDLINE: Melanoma, SOXE Transcription Factors, Focal Adhesion Kinase 1, Receptor, EphA2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Melanoma heterogeneity contributes to increased metastatic potential. Although a subpopulation characterized by MITF low /AXL high has been linked to invasiveness, the underlying mechanisms remain unclear. In this study, we identified cell migration‐related gene sets as significantly enriched after the knockdown of SOX10 in melanoma. Both in silico analysis and in vitro analysis identified ITGA3 and EPHA2 as downstream effectors of SOX10‐mediated migration, essential for cell adhesion and random motility, respectively. Moreover, the oncogenic activation of MAPK was necessary for increased random motility through EphA2 phosphorylation at the Ser 897 residue. We also identified IRF1 as an upstream regulator of both ITGA3 and EphA2 after the knockdown of SOX10. Notably, IRF1 suppression or the treatment with the FAK inhibitor, defactinib, significantly reduced melanoma metastasis in vivo. These findings demonstrate that the reduced expression of SOX10 promotes melanoma metastasis through the IRF1‐ITGA3/EphA2‐FAK pathway and highlight FAK inhibition as a potential therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
- Division of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, Toyama, Japan.
ORCID-Profile: Soichiro Sasaki, Yoshihiro Hayakawa, Satoru Yokoyama
Förderung
- Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research
- Japan Society for the Promotion of Science
Zitieren
APA
Kaminaka, R., Takahashi, N., Nishizawa, M., Sasaki, S., Sugihara, Y., Matsumoto, M., Taniguchi, R., Zhou, Y., Hayakawa, Y., Sakurai, H., & Yokoyama, S. (2025). SOX10 Regulates Melanoma Metastasis Through the IRF1 ‐ ITGA3 / EphA2 ‐ FAK Pathway. Cancer Science, 116(11), 3052-3065. https://doi.org/10.1111/cas.70173
Vancouver
Kaminaka R, Takahashi N, Nishizawa M, Sasaki S, Sugihara Y, Matsumoto M, et al. SOX10 Regulates Melanoma Metastasis Through the IRF1 ‐ ITGA3 / EphA2 ‐ FAK Pathway. Cancer Science. 2025;116(11):3052-3065. doi:10.1111/cas.70173
BibTeX
@article{Kaminaka2025,
author = {Kaminaka, Ryuya and Takahashi, Nana and Nishizawa, Mayu and Sasaki, Soichiro and Sugihara, Yuichiro and Matsumoto, Minoru and Taniguchi, Ryoma and Zhou, Yue and Hayakawa, Yoshihiro and Sakurai, Hiroaki and Yokoyama, Satoru},
title = {SOX10 Regulates Melanoma Metastasis Through the IRF1 ‐ ITGA3 / EphA2 ‐ FAK Pathway},
journal = {Cancer Science},
year = {2025},
volume = {116},
number = {11},
pages = {3052--3065},
doi = {10.1111/cas.70173}
}
EUVIMED